Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

Maryam A.Y. Al-Nesf; Houari B. Abdesselem; Ilham Bensmail; Shahd Ibrahim; Walaa A.H. Saeed; Sara S.I. Mohammed; Almurtada Razok; Hashim Alhussain; Reham M.A. Aly; Muna Al Maslamani; Khalid Ouararhni; Mohamad Y. Khatib; Ali Ait Hssain; Ali S. Omrani; Saad Al-Kaabi; Abdullatif Al Khal; Asmaa A. Al-Thani; Waseem Samsam; Abdulaziz Farooq; Jassim Al-Suwaidi; Mohammed Al-Maadheed; Heba H. Al-Siddiqi; Alexandra E. Butler; Julie V. Decock; Vidya Mohamed-Ali; Fares Al-Ejeh

doi:10.1038/s41467-022-28639-4

Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

Maryam A.Y. Al-Nesf
, Houari B. Abdesselem
, Ilham Bensmail
, Shahd Ibrahim
, Walaa A.H. Saeed
, Sara S.I. Mohammed
, Almurtada Razok
, Hashim Alhussain
, Reham M.A. Aly
, Muna Al Maslamani
, Khalid Ouararhni
, Mohamad Y. Khatib
, Ali Ait Hssain
, Ali S. Omrani
, Saad Al-Kaabi
, Abdullatif Al Khal
, Asmaa A. Al-Thani
, Waseem Samsam
, Abdulaziz Farooq
, Jassim Al-Suwaidi

Mohammed Al-Maadheed, Heba H. Al-Siddiqi, Alexandra E. Butler, Julie V. Decock, Vidya Mohamed-Ali, Fares Al-Ejeh^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

Abstract

COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients.

Original language	English
Article number	946
Journal	Nature Communications
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41467-022-28639-4
Publication status	Published - Dec 2022

Access to Document

10.1038/s41467-022-28639-4

Cite this

Al-Nesf, M. A. Y., Abdesselem, H. B., Bensmail, I., Ibrahim, S., Saeed, W. A. H., Mohammed, S. S. I., Razok, A., Alhussain, H., Aly, R. M. A., Al Maslamani, M., Ouararhni, K., Khatib, M. Y., Hssain, A. A., Omrani, A. S., Al-Kaabi, S., Al Khal, A., Al-Thani, A. A., Samsam, W., Farooq, A., ... Al-Ejeh, F. (2022). Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nature Communications, 13(1), Article 946. https://doi.org/10.1038/s41467-022-28639-4

@article{fc6a76728b6743f6ba0e1104421505ff,

title = "Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications",

abstract = "COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients.",

author = "Al-Nesf, \{Maryam A.Y.\} and Abdesselem, \{Houari B.\} and Ilham Bensmail and Shahd Ibrahim and Saeed, \{Walaa A.H.\} and Mohammed, \{Sara S.I.\} and Almurtada Razok and Hashim Alhussain and Aly, \{Reham M.A.\} and \{Al Maslamani\}, Muna and Khalid Ouararhni and Khatib, \{Mohamad Y.\} and Hssain, \{Ali Ait\} and Omrani, \{Ali S.\} and Saad Al-Kaabi and \{Al Khal\}, Abdullatif and Al-Thani, \{Asmaa A.\} and Waseem Samsam and Abdulaziz Farooq and Jassim Al-Suwaidi and Mohammed Al-Maadheed and Al-Siddiqi, \{Heba H.\} and Butler, \{Alexandra E.\} and Decock, \{Julie V.\} and Vidya Mohamed-Ali and Fares Al-Ejeh",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41467-022-28639-4",

language = "English",

volume = "13",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

Al-Nesf, MAY, Abdesselem, HB, Bensmail, I, Ibrahim, S, Saeed, WAH, Mohammed, SSI, Razok, A, Alhussain, H, Aly, RMA, Al Maslamani, M, Ouararhni, K, Khatib, MY, Hssain, AA, Omrani, AS, Al-Kaabi, S, Al Khal, A, Al-Thani, AA, Samsam, W, Farooq, A, Al-Suwaidi, J, Al-Maadheed, M, Al-Siddiqi, HH, Butler, AE, Decock, JV, Mohamed-Ali, V & Al-Ejeh, F 2022, 'Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications', Nature Communications, vol. 13, no. 1, 946. https://doi.org/10.1038/s41467-022-28639-4

TY - JOUR

T1 - Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

AU - Al-Nesf, Maryam A.Y.

AU - Abdesselem, Houari B.

AU - Bensmail, Ilham

AU - Ibrahim, Shahd

AU - Saeed, Walaa A.H.

AU - Mohammed, Sara S.I.

AU - Razok, Almurtada

AU - Alhussain, Hashim

AU - Aly, Reham M.A.

AU - Al Maslamani, Muna

AU - Ouararhni, Khalid

AU - Khatib, Mohamad Y.

AU - Hssain, Ali Ait

AU - Omrani, Ali S.

AU - Al-Kaabi, Saad

AU - Al Khal, Abdullatif

AU - Al-Thani, Asmaa A.

AU - Samsam, Waseem

AU - Farooq, Abdulaziz

AU - Al-Suwaidi, Jassim

AU - Al-Maadheed, Mohammed

AU - Al-Siddiqi, Heba H.

AU - Butler, Alexandra E.

AU - Decock, Julie V.

AU - Mohamed-Ali, Vidya

AU - Al-Ejeh, Fares

PY - 2022/12

Y1 - 2022/12

N2 - COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients.

AB - COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients.

UR - https://www.scopus.com/pages/publications/85124777237

U2 - 10.1038/s41467-022-28639-4

DO - 10.1038/s41467-022-28639-4

M3 - Article

C2 - 35177642

AN - SCOPUS:85124777237

SN - 2041-1723

VL - 13

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 946

ER -

Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

Abstract

Access to Document

Other files and links

Fingerprint

Cite this